LED Medical Diagnostics Inc. (TSX.V: LMD), a developer of tissue visualization detection technologies for the medical industry, announced today that its VELscope Vx® Enhanced Oral Assessment device is enhancing the health of dental practices as well as the health of their patients.
“While the main reason most dentists acquire a VELscope Vx® is to provide the best possible oral and systemic health care to their patients,” said Peter Whitehead, founder and CEO of VELscope Vx® manufacturer LED Dental and its LED Medical Diagnostics parent, “many of those dentists are finding that our technology is also good for the health of the dental practice itself.”
According to Mr. Whitehead, VELscope Vx®-equipped practices are benefiting from patient word of mouth. “Our patients love the fact that we include complimentary VELscope Vx® screenings at every hygiene visit to complement our conventional oral exams,” said Kevin Huff, D.D.S., M.A.G.D. “They often refer their friends and family members to us. The VELscope Vx® has been a valuable marketing tool over the past several years that, I firmly believe, also happens to significantly enhance the value of the care that we provide.”
In addition, medical doctors who suspect that their patients might have oral cancer often send their patients to dentists who have a VELscope Vx®. “Local oncologists and ENTs have referred their patients to me because of our use of the VELscope Vx®,” said John C. Comisi, D.D.S., M.A.G.D.. He added, “Patients have stated they have come specifically to my office because of the thorough head and neck screenings we do and because of the use of this technology to aid in our screenings.”
According to Mr. Whitehead, a recent survey of dental practices that use the VELscope Vx® revealed that the device helped the average practice add four new patients during its first year in use, while some practices added over 20 new patients. In addition, the vast majority of dentists indicated a high level of satisfaction with the VELscope Vx®’s impact on the practice’s profitability despite the fact that one-third of them do not charge for the VELscope Vx® exam. The remaining two-thirds charge an average exam fee of $30 to $35. While most patients consider this fee to be very reasonable—particularly those whose insurance plans reimburse them for the cost—the added income to the practice over the course of a year can be very significant.
“VELscope Vx® users are to be applauded for stepping up and making an investment they firmly and rightly believe will enhance the health of their patients,” said Mr. Whitehead. “It is very gratifying to know that these dental practices are being rewarded for their unselfish and caring actions with increased patient counts and a healthier bottom line.”